

Datasheet for ABIN7538788  
**Periaxin Protein (PRX) (MYC tag)**



[Go to Product page](#)

## Overview

Quantity:	2 x 100 µg
Target:	Periaxin (PRX)
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	cVLP
Purification tag / Conjugate:	This Periaxin protein is labelled with MYC tag.
Application:	ELISA, Western Blotting (WB), Nanoparticle Tracking Analysis (NTA)

## Product Details

Purpose:	Set: cVLP of SARS-CoV-2 (M+E+N) PRX + Control VLP of SARS-CoV-2 (M+E+N)
Characteristics:	Chimeric SARS-CoV-2 virus-like particles (cVLP) were produced in HEK cells by co-expression of the membrane-, envelope- and nucleoprotein with a membrane bound target protein. The VLPs do not contain the viral genome, cannot replicate and are not infectious.
Purification:	Polyethylene glycol precipitation
Components:	Set contains: (ABIN7538791) and (ABIN7538794).
Biological Activity Comment:	active

## Target Details

Target:	Periaxin (PRX)
Alternative Name:	Periaxin ( <a href="#">PRX Products</a> )

## Target Details

---

**Background:** Periaxin is a protein that in humans is encoded by the PRX gene. This gene encodes a protein involved in peripheral nerve myelin upkeep. The encoded protein contains 2 PDZ domains which were named after PSD95 (post synaptic density protein), DlgA (Drosophila disc large tumor suppressor), and ZO1 (a mammalian tight junction protein). Two alternatively spliced transcript variants have been described for this gene which encode different protein isoforms and which are targeted differently in the Schwann cell. Mutations in this gene cause Charcot-Marie-Tooth neuropathy, type 4F and Dejerine-Sottas neuropathy. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus (genus: Betacoronavirus, subgenus: Sarbecovirus) that was identified as the cause of COVID-19 disease in early 2020.

## Application Details

---

**Application Notes:** Applications: Immunogenic antigen, antigen for ELISA and Western blot.  
Western blot: 1-10 µg, ELISA: 1-5 µg/mL

**Comment:** Virus-like Particles are multiprotein complexes that resemble a native virus, but lack the genetic information. Therefore, VLPs are safe to handle in numerous fields of applications. For example, VLPs can be applied as antigen in serological assays (e.g. ELISA), or serve as reference material to standardize the performance of different diagnostic tests (e.g. rapid antigen tests or ELISA). Due to the self-adjuvanting properties of VLPs is the most common application of VLPs the use as antigen for immunizations for vaccine development or antibody discovery campaigns.

**Restrictions:** For Research Use only

## Handling

---

**Format:** Liquid

**Concentration:** Lot specific

**Buffer:** PBS

**Storage:** -80 °C

**Storage Comment:** - 80°C